Equity Profile

GRAL

GRAIL, Inc.

Health CareBiotechnology$3.1B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GRAIL is managing its costs.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests. Operating in the health care sector, GRAIL aims to improve patient outcomes by enabling earlier diagnosis, which is crucial for effective treatment.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In Q1-2026, GRAIL reported an EPS of -$2.29, which was better than the expected -$3.00, marking a 23.67% surprise. However, the stock fell 2.26% the following day, indicating market skepticism despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating another earnings report from GRAIL that may show improved performance, especially given the company's history of beating EPS estimates. However, uncertainty remains due to the lack of revenue guidance and overall market conditions.

Bull Case

If GRAIL continues its trend of beating EPS estimates, it could signal strong operational efficiency and growing market acceptance of its cancer detection tests, potentially leading to a positive stock reaction.

Bear Case

Conversely, if GRAIL fails to meet expectations or provides no clear guidance on revenue, it could raise concerns about its growth trajectory and lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be this quarter, and how does it compare to previous quarters?

Given GRAIL's history of beating EPS estimates, this figure will be critical in determining market sentiment and stock movement.

Will there be any guidance on revenue growth or product adoption rates?

Clear guidance on revenue will help investors gauge the company's growth potential and market demand for its cancer detection tests.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GRAIL's ability to maintain its EPS surprise trend, as the company has consistently outperformed expectations despite market skepticism.

Supporting Evidence

GRAIL has a 100% EPS beat rate over the last five quarters, indicating strong operational management.

The options market is pricing in an 18.37% move, suggesting that investors expect significant volatility, which could indicate underlying confidence.

Recent historical performance shows that even small beats have led to positive stock reactions, indicating potential for upside.

Key Risk

If GRAIL's EPS comes in below -$2.50, it could significantly undermine the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will either reinforce GRAIL's growth narrative or highlight potential weaknesses in its business model.

Bull Confirmed If

An EPS of -$2.00 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$2.50 would confirm the bear case, raising concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests a potential stock increase of around 1.9%, confirming the company's operational strength.

In-Line / Cautious

If results are in line but lack clear guidance, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

If GRAIL misses expectations, the stock could decline, with historical patterns suggesting a drop similar to the average reaction of -2.26%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product adoption rates for GRAIL's cancer detection tests.
2Management's commentary on cost management and operational efficiency.
3Insights into competitive positioning in the biotechnology space.
4Any new partnerships or collaborations that could enhance growth prospects.
5Guidance on future revenue expectations or market expansion plans.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GRAIL is managing its costs.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

Bear Case

Conversely, if GRAIL fails to meet expectations or provides no clear guidance on revenue, it could raise concerns about its growth trajectory and lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be this quarter, and how does it compare to previous quarters?

Given GRAIL's history of beating EPS estimates, this figure will be critical in determining market sentiment and stock movement.

Will there be any guidance on revenue growth or product adoption rates?

Clear guidance on revenue will help investors gauge the company's growth potential and market demand for its cancer detection tests.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GRAIL's ability to maintain its EPS surprise trend, as the company has consistently outperformed expectations despite market skepticism.

Supporting Evidence

GRAIL has a 100% EPS beat rate over the last five quarters, indicating strong operational management.

The options market is pricing in an 18.37% move, suggesting that investors expect significant volatility, which could indicate underlying confidence.

Recent historical performance shows that even small beats have led to positive stock reactions, indicating potential for upside.

Key Risk

If GRAIL's EPS comes in below -$2.50, it could significantly undermine the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will either reinforce GRAIL's growth narrative or highlight potential weaknesses in its business model.

Bull Confirmed If

An EPS of -$2.00 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$2.50 would confirm the bear case, raising concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests a potential stock increase of around 1.9%, confirming the company's operational strength.

In-Line / Cautious

If results are in line but lack clear guidance, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

If GRAIL misses expectations, the stock could decline, with historical patterns suggesting a drop similar to the average reaction of -2.26%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product adoption rates for GRAIL's cancer detection tests.
2Management's commentary on cost management and operational efficiency.
3Insights into competitive positioning in the biotechnology space.
4Any new partnerships or collaborations that could enhance growth prospects.
5Guidance on future revenue expectations or market expansion plans.